



COVID Vaccine Information

Key attributes of the COVID vaccines which have received Emergency Use Authorization (EUA) or full approval from the Food and Drug Administration

	Moderna	Pfizer/BioNTech	J&J/Janssen
# of doses (initial series), not immunocompromised	2	2	1
# of doses (initial series), immune-compromised	3	3	n/a
Booster dose	Booster dose does not need to be the same product.	Booster dose does not need to be the same product.	Booster dose does not need to be the same product.
Interval between doses for initial series, not immunocompromised	28 days	21 days	n/a
Interval to third dose (immunocompromised)	28 days	28 days	n/a
Interval for boosters (after initial series)	5 months	5 months	2 months
Lower age bound	18 years for both initial series and booster	5 years for initial series (including for immunocompromised), 12 years for booster	18 years for both initial series and booster
Product type	mRNA/liquid nanoparticle	mRNA/liquid nanoparticle	DNA/adenovirus (viral vector)
Emergency Use Authorization	December 18, 2021	December 11, 2021	February 27, 2021
Full Authorization Status (BLA approved)	NEW: January 31, 2022 (18 years +)	August 23, 2021 (16 years +)	
Various FDA considerations	"Likely association" with reported cases of heart inflammation in young adults	"Likely association" with reported cases of heart inflammation in young adults	Guillain-Barré syndrome , Thrombosis with thrombocytopenia syndrome (TTS), and immune thrombocytopenia (ITP)

NEW: [Press Release](#): Coronavirus (COVID-19) Update: FDA Takes Key Action By Approving Second COVID-19 Vaccine